Mechanism of Action of Anti-CD20 Drugs
Anti-CD20 monoclonal antibodies (such as rituximab, ocrelizumab, and ofatumumab) work by binding to the CD20 protein on B-cell surfaces, leading to B-cell destruction through three primary mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis 1.
How Anti-CD20 Drugs Eliminate B-Cells
The specific mechanism varies by drug formulation:
- ADCC-predominant drugs (like ublituximab and ocrelizumab): Natural killer cells recognize the antibody-coated B-cells and destroy them 2, 3
- CDC-predominant drugs (like ofatumumab): The complement cascade is activated, forming membrane attack complexes that lyse B-cells 3
- Mixed mechanisms (like rituximab): Utilizes both ADCC and CDC pathways 1
The CD20 antigen density on B-cell surfaces directly determines treatment efficacy—higher CD20 expression correlates with better cell lysis 4. This is why CD20 levels matter for predicting treatment response.
Why CD19 Levels Are Measured
CD19 is measured because it serves as a surrogate marker for total B-cell populations, including those that may not express CD20 or have lost CD20 expression after anti-CD20 therapy 5.
Clinical Rationale for CD19 Monitoring
CD19 monitoring is critical for several reasons:
- Broader B-cell assessment: CD19 is expressed on all B-cells from early pre-B cells through mature B-cells, whereas CD20 is absent on plasma cells and early B-cell precursors 5
- Detecting treatment resistance: Loss of CD20 expression is a known resistance mechanism to anti-CD20 therapy. CD19 levels help identify whether B-cells are truly depleted or have simply downregulated CD20 6
- Guiding CAR T-cell therapy: Before initiating CD19-directed CAR T-cell therapy or CD3×CD20 bispecific antibodies, rebiopsy to confirm CD20 positivity is recommended, as CD19 may still be present when CD20 is lost 6
Why Immunoglobulin Levels Need Monitoring
Immunoglobulin monitoring is mandatory because anti-CD20 therapy causes prolonged B-cell depletion leading to hypogammaglobulinemia in up to 53% of patients, which significantly increases infection risk, particularly for bacterial, viral, and fungal pathogens 5, 7.
Monitoring Protocol and Intervention Thresholds
Frequency of Monitoring
- Quarterly immunoglobulin measurements (IgG, IgM, IgA) throughout treatment 7
- More frequent monitoring if infections occur or levels are declining
Critical Intervention Thresholds
Initiate IVIG replacement therapy (400-500 mg/kg monthly) when:
- IgG levels fall below 400-600 mg/dL AND
- Patient experiences serious or recurrent infections (particularly bacterial) 5
Continue IVIG until serum IgG normalizes and infections resolve 5.
Risk Factors for Hypogammaglobulinemia
Certain factors predict higher risk:
- Rituximab causes hypogammaglobulinemia more frequently and earlier compared to other anti-CD20 agents 7
- High disease activity (elevated ESR, SLEDAI scores) predicts poor immunological response 8
- Combination immunosuppression (mycophenolate mofetil, high-dose corticosteroids) increases risk 8
- Longer treatment duration progressively depletes plasma cells 9
Infection Prevention Strategy
Before and during anti-CD20 therapy:
- Prophylaxis for Pneumocystis pneumonia should be considered in all patients 10
- Delay vaccination 6 months after last anti-CD20 dose for optimal antibody response 11
- Monitor for opportunistic infections including CMV, fungal infections, and atypical bacteria 10
Common Pitfalls to Avoid
- Do not assume normal B-cell function based solely on CD20 depletion—plasma cells producing antibodies may be separately affected
- Do not wait for severe infections to check immunoglobulin levels—quarterly monitoring catches hypogammaglobulinemia early
- Do not give IVIG prophylactically to all patients—reserve for those with documented hypogammaglobulinemia AND recurrent infections 5
- Do not interpret rising IgM during rituximab as treatment failure—this "IgM flare" occurs in 50% of patients and is not associated with worse outcomes 12
The evidence strongly supports that hypogammaglobulinemia occurs earlier and more frequently with rituximab than with newer agents like ofatumumab 7, which should inform drug selection in patients at high infection risk.